[Proceedings: Evaluation of serum dopamine-beta-hydroxylase determination].

I. Hara,M. Mizuno,A. Tomita

1974-02-20

Abstract:

What problem does this paper attempt to address?

Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo

Casper de Boer,Zachary Armstrong,Vincent A. J. Lit,Uri Barash,Gijs Ruijgrok,Ilanit Boyango,Merle M. Weitzenberg,Sybrin P. Schröder,Alexi J. C. Sarris,Nico J. Meeuwenoord,Pedro Bule,Yasmine Kayal,Neta Ilan,Jeroen D. C. Codée,Israel Vlodavsky,Herman S. Overkleeft,Gideon J. Davies,Liang Wu

DOI: https://doi.org/10.1073/pnas.2203167119

2022-07-28

Abstract:Heparan sulfate proteoglycans (HSPGs) mediate essential interactions throughout the extracellular matrix (ECM), providing signals that regulate cellular growth and development. Altered HSPG composition during tumorigenesis strongly aids cancer progression. Heparanase (HPSE) is the principal enzyme responsible for extracellular heparan sulfate catabolism and is markedly up-regulated in aggressive cancers. HPSE overactivity degrades HSPGs within the ECM, facilitating metastatic dissemination and releasing mitogens that drive cellular proliferation. Reducing extracellular HPSE activity reduces cancer growth, but few effective inhibitors are known, and none are clinically approved. Inspired by the natural glycosidase inhibitor cyclophellitol, we developed nanomolar mechanism-based, irreversible HPSE inhibitors that are effective within physiological environments. Application of cyclophellitol-derived HPSE inhibitors reduces cancer aggression in cellulo and significantly ameliorates murine metastasis. Mechanism-based irreversible HPSE inhibition is an unexplored anticancer strategy. We demonstrate the feasibility of such compounds to control pathological HPSE-driven malignancies.

multidisciplinary sciences
A New Synthesized Dicarboxylated Oxy-Heparin Efficiently Attenuates Tumor Growth and Metastasis

Li Li,Uri Barash,Neta Ilan,Malik Farhoud,Xiao Zhang,Israel Vlodavsky,Jin-Ping Li

DOI: https://doi.org/10.3390/cells13030211

IF: 6

2024-01-24

Cells

Abstract:Heparanase (Hpa1) is expressed by tumor cells and cells of the tumor microenvironment and functions to remodel the extracellular matrix (ECM) and regulate the bioavailability of ECM-bound factors that support tumor growth. Heparanase expression is upregulated in human carcinomas, sarcomas, and hematological malignancies, correlating with increased tumor metastasis, vascular density, and shorter postoperative survival of cancer patients, and encouraging the development of heparanase inhibitors as anti-cancer drugs. Among these are heparin/HS mimetics, the only heparanase-inhibiting compounds that are being evaluated in clinical trials. We have synthesized dicarboxylated oxy-heparins (DCoxHs) containing three carboxylate groups per split residue (DC-Hep). The resulting lead compound (termed XII) was upscaled, characterized, and examined for its effectiveness in tumor models. Potent anti-tumorigenic effects were obtained in models of pancreatic carcinoma, breast cancer, mesothelioma, and myeloma, yielding tumor growth inhibition (TGI) values ranging from 21 to 70% and extending the survival time of the mice. Of particular significance was the inhibition of spontaneous metastasis in an orthotopic model of breast carcinoma following resection of the primary tumor. It appears that apart from inhibition of heparanase enzymatic activity, compound XII reduces the levels of heparanase protein and inhibits its cellular uptake and activation. Heparanase-dependent and -independent effects of XII are being investigated. Collectively, our pre-clinical studies with compound XII strongly justify its examination in cancer patients.

cell biology
Targeted glycan degradation potentiates the anticancer immune response in vivo

Melissa A. Gray,Michal A. Stanczak,Natália R. Mantuano,Han Xiao,Johan F. A. Pijnenborg,Stacy A. Malaker,Caitlyn L. Miller,Payton A. Weidenbacher,Julia T. Tanzo,Green Ahn,Elliot C. Woods,Heinz Läubli,Carolyn R. Bertozzi

DOI: https://doi.org/10.1038/s41589-020-0622-x

IF: 14.8

2020-08-17

Nature Chemical Biology

Abstract:Currently approved immune checkpoint inhibitor therapies targeting the PD-1 and CTLA-4 receptor pathways are powerful treatment options for certain cancers; however, most patients across cancer types still fail to respond. Consequently, there is interest in discovering and blocking alternative pathways that mediate immune suppression. One such mechanism is an upregulation of sialoglycans in malignancy, which has been recently shown to inhibit immune cell activation through multiple mechanisms and therefore represents a targetable glycoimmune checkpoint. Since these glycans are not canonically druggable, we designed an αHER2 antibody–sialidase conjugate that potently and selectively strips diverse sialoglycans from breast cancer cells. In syngeneic breast cancer models, desialylation enhanced immune cell infiltration and activation and prolonged the survival of mice, an effect that was dependent on expression of the Siglec-E checkpoint receptor found on tumor-infiltrating myeloid cells. Thus, antibody–sialidase conjugates represent a promising modality for glycoimmune checkpoint therapy.

biochemistry & molecular biology
Design Principle of Heparanase Inhibitors: A Combined In Vitro and In Silico Study

Yuzhao Zhang,Meijun Xiong,Zixin Chen,Gustavo Seabra,Jun Liu,Chenglong Li,Lina Cui

DOI: https://doi.org/10.1021/acsmedchemlett.3c00268

2024-07-17

ACS Medicinal Chemistry Letters

Abstract:Heparanase (HPSE) is an enzyme that cleaves heparan sulfate (HS) side chains from heparan sulfate proteoglycans (HSPGs). Overexpression of HPSE is associated with various types of cancer, inflammation, and immune disorders, making it a highly promising therapeutic target. Previously developed HPSE inhibitors that have advanced to clinical trials are polysaccharide-derived compounds or their mimetics; however, these molecules tend to suffer from poor bioavailability, side effects via targeting...

chemistry, medicinal
Chemoenzymatic synthesis of sulfur-linked sugar polymers as heparanase inhibitors

Peng He,Xing Zhang,Ke Xia,Dixy E. Green,Sultan Baytas,Yongmei Xu,Truong Pham,Jian Liu,Fuming Zhang,Andrew Almond,Robert J. Linhardt,Paul L. DeAngelis

DOI: https://doi.org/10.1038/s41467-022-34788-3

IF: 16.6

2022-12-02

Nature Communications

Abstract:Abstract Complex carbohydrates (glycans) are major players in all organisms due to their structural, energy, and communication roles. This last essential role involves interacting and/or signaling through a plethora of glycan-binding proteins. The design and synthesis of glycans as potential drug candidates that selectively alter or perturb metabolic processes is challenging. Here we describe the first reported sulfur-linked polysaccharides with potentially altered conformational state(s) that are recalcitrant to digestion by heparanase, an enzyme important in human health and disease. An artificial sugar donor with a sulfhydryl functionality is synthesized and enzymatically incorporated into polysaccharide chains utilizing heparosan synthase. Used alone, this donor adds a single thio-sugar onto the termini of nascent chains. Surprisingly, in chain co-polymerization reactions with a second donor, this thiol-terminated heparosan also serves as an acceptor to form an unnatural thio-glycosidic bond (‘ S -link’) between sugar residues in place of a natural ‘ O -linked’ bond. S -linked heparan sulfate analogs are not cleaved by human heparanase. Furthermore, the analogs act as competitive inhibitors with > ~200-fold higher potency than expected; as a rationale, molecular dynamic simulations suggest that the S -link polymer conformations mimic aspects of the transition state. Our analogs form the basis for future cancer therapeutics and modulators of protein/sugar interactions.

multidisciplinary sciences
Non-Anticoagulant Heparan Sulfate from the Ascidian Phallusia nigra Prevents Colon Carcinoma Metastasis in Mice by Disrupting Platelet-Tumor Cell Interaction

Christiane F. S. Silva,Juliana M. Motta,Felipe C. O. B. Teixeira,Angélica M. Gomes,Eduardo Vilanova,Eliene O. Kozlowski,Lubor Borsig,Mauro S. G. Pavão,Christiane Silva,Juliana Motta,Felipe Teixeira,Angélica Gomes,Eliene Kozlowski,Mauro Pavão

DOI: https://doi.org/10.3390/cancers12061353

2020-05-26

Cancers

Abstract:Although metastasis is the primary cause of death in patients with malignant solid tumors, efficient anti-metastatic therapies are not clinically available currently. Sulfated glycosaminoglycans from marine sources have shown promising pharmacological effects, acting on different steps of the metastatic process. Oversulfated dermatan sulfates from ascidians are effective in preventing metastasis by inhibition of P-selectin, a platelet surface protein involved in the platelet-tumor cell emboli formation. We report in this work that the heparan sulfate isolated from the viscera of the ascidian Phallusia nigra drastically attenuates metastases of colon carcinoma cells in mice. Our in vitro and in vivo assessments demonstrate that the P. nigra glycan has very low anticoagulant and antithrombotic activities and a reduced hypotension potential, although it efficiently prevented metastasis. Therefore, it may be a promising candidate for the development of a novel anti-metastatic drug.

oncology
Epigenetic Targeting of Heparan Sulfate 3- O- and 6- O-Sulfation in Breast Cancer Cells: Prospects for Attenuating Prothrombotic Tumor Cell Activities

Nico Bückreiß,Marie Schulz-Fincke,Philipp König,Marco Maccarana,Toin H van Kuppevelt,Jin-Ping Li,Martin Götte,Gerd Bendas

DOI: https://doi.org/10.1021/acsptsci.4c00295

2024-07-30

Abstract:The deregulation of cell surface heparan sulfate proteoglycans (HSPGs) is a main issue of cancer cells for increasing their malignancy. In these terms, the sulfation pattern of HS, created by an orchestrated activity of enzymes balancing a site-specific sulfation, is of key importance. These enzymes are often deregulated by epigenetic processes in cancer, e.g., being silenced by DNA hypermethylation. Here, we address this issue in human breast cancer cell lines aiming to target epigenetic processes to reactivate HS sulfation, shifting HS into an antithrombotic phenotype for which 3-O-sulfation is particularly important. Treatment of MCF-7 and MDA-MB-231 cells with nontoxic concentrations of 5-azacytidine (azacytidine) and 5-fluoro-2'-deoxycytidine (FdCyd) as DNMT inhibitors or vorinostat for targeting HDAC increased HS3-O-sulfation remarkably, as confirmed by fluorescence microscopy, by upregulating HS3-O-sulfotransferases, detected by quantitative real-time polymerase chain reaction and Western blot. Flow cytometry and microscopic approaches confirm that upon inhibitor treatment, increased HS3-O-sulfation improves cell binding to antithrombin, leading to an antithrombotic activity. Nevertheless, only azacytidine- and vorinostat-treated cells display anticoagulative properties, represented by attenuated thrombin formation, a lower activation of human platelet aggregation, or ATP release. In contrast, FdCyd additionally upregulated tissue factor expression in both cell lines, overshadowing the anticoagulant effects of HS, leading to an overall prothrombotic phenotype. Our data provide evidence for the first time that targeting epigenetic processes in HS sulfation is a valuable means to foster anticoagulative cell properties for decreasing malignancy and metastatic potency. These data warrant further investigations to fine-tune epigenetic targeting and to search for potential biomarkers attributed to these activities.
Abstract 3105: Design principle of heparanase inhibitors: A combined in vitro and in silico study

Yuzhao Zhang,Meijun Xiong,Zixin Chen,Gustavo Seabra,Jun Liu,Chenglong Li,Lina Cui

DOI: https://doi.org/10.1158/1538-7445.am2023-3105

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Heparanase (HPSE) is an endo-β-D-glucuronidase and the only known enzyme responsible for the cleavage of heparan sulfate (HS) side chains from heparan sulfate proteoglycans (HSPGs). The enzymatic activity of HPSE mediates ECM remodeling, regulates growth factors, and modulates related signaling pathways, thus HPSE has emerged as a novel therapeutic target for various diseases, including most types of cancers. In the last two decades, a number of HPSE inhibitors have been reported by several labs worldwide, with most of them belonging to the heparan sulfate mimics category. So far, few of the small molecule HPSE inhibitors have progressed into clinical trials and none has gained approval by regulatory agencies, leaving a blank in HPSE drug discovery. Here we present the discovery of a novel HPSE small molecule inhibitor by high-throughput screening using an ultrasensitive HPSE enzymatic detecting probe developed in our lab and provide the mechanisms of action behind the small molecule’s HPSE inhibitory activity. By doing a series of molecular dynamics (MD) simulations, we discovered the binding profiles on the derivatives of the lead compound. We summarized the essential structural features of the lead compound to provide insights into the design of future HPSE small molecule inhibitors. Citation Format: Yuzhao Zhang, Meijun Xiong, Zixin Chen, Gustavo Seabra, Jun Liu, Chenglong Li, Lina Cui. Design principle of heparanase inhibitors: A combined in vitro and in silico study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3105.

oncology
Synthesis and Detection of BODIPY‐, Biotin‐, and 19F‐ Labeled Single‐Entity Dendritic Heparan Sulfate Mimetics

Sam Spijkers-Shaw,Rory G Devlin,Nicholas J Shields,Xiang Feng,Tessa Peck,Georgia Lenihan-Geels,Connor Davis,Sarah L Young,Anne C La Flamme,Olga V Zubkova

DOI: https://doi.org/10.1002/anie.202316791

2024-02-04

Angewandte Chemie International Edition

Abstract:Heparin and heparan sulfate (HS) are naturally occurring mammalian glycosaminoglycans, and their synthetic and semi-synthetic mimetics have attracted significant interest as potential therapeutics. However, understanding the mechanism of action by which HS, heparin, and HS mimetics have a biological effect is difficult due to their highly charged nature, broad protein interactomes, and variable structures. Here we report that a library of novel single-entity dendritic mimetics conjugated to BODIPY, Fluorine-19 (19F), and biotin was synthesized for imaging and localization studies. The novel dendritic scaffold allowed for the conjugation of labeling moieties without reducing the number of sulfated capping groups, thereby better mimicking the multivalent nature of HS-protein interactions. The 19F labeled mimetics were assessed in phantom studies and were detected at concentrations as low as 5 mM. Flow cytometric studies using a fluorescently labeled mimetic showed that the compound associated with immune cells from tumors more readily than splenic counterparts and was directed to endosomal-lysosomal compartments within immune cells and cancer cells. Furthermore, the fluorescently labeled mimetic crossed the blood-brain barrier and was detectable in brain-infiltrating immune cells 24 hours after treatment.

chemistry, multidisciplinary
Non-anticoagulant heparins and inhibition of cancer

Benito Casu,Israel Vlodavsky,Ralph D Sanderson

DOI: https://doi.org/10.1159/000175157

Abstract:Low-molecular-weight heparins (LMWH) appear to prolong survival of patients with cancer. Such a beneficial effect is thought to be associated with interruption of molecular mechanisms involving the heparan sulfate (HS) chains of cell surface and extracellular matrix proteoglycans (HSPGs), growth factors and their receptors, heparanase, and selectins. The beneficial effects of heparin species could also be associated with their ability to release tissue factor pathway inhibitor from endothelium. The utility of heparin and LMWH as anticancer drugs is limited due to their anticoagulant properties. Non-anticoagulant heparins can be obtained either by removing chains containing the antithrombin-binding sequence, or by inactivating critical functional groups or units of this sequence. The non-anticoagulant heparins most extensively studied are regioselectively desulfated heparins and 'glycol-split' heparins. Some modified heparins of both types are potent inhibitors of heparanase. A number of them also attenuate metastasis in experimental models. With cancer cells overexpressing selectins, heparin-mediated inhibition of tumor cells-platelets aggregation and tumor cell interaction with the vascular endothelium appears to be the prevalent mechanism of attenuation of early stages of metastasis. The structural requirements for inhibition of growth factors, heparanase, and selectins by heparin derivatives are somewhat different for the different activities. An N-acetylated, glycol-split heparin provides an example of application of a non-anticoagulant heparin that inhibits cancer in animal models without unwanted side effects. Delivery of this compound to mice bearing established myeloma tumors dramatically blocked tumor growth and progression.
Heparan sulfate analogues regulate tumor-derived exosome formation that attenuates exosome functions in tumor processes

Xiaotao Wu,Mingzhu Kang,Danhui Wang,Min Zhu,Yiwei Hu,Yan Zhang,Chao Deng,Jinghua Chen,Liping Teng

DOI: https://doi.org/10.1016/j.ijbiomac.2021.07.110

IF: 8.2

2021-09-01

International Journal of Biological Macromolecules

Abstract:Heparan sulfate (HS) is involved in many biological activities, including the biogenesis and uptake of exosomes, which are related to the occurrence and development of tumors. This study investigated the role of HS analogues (heparin, low molecular weight heparin, and 6-O-desulfated heparin) in modulating exosome secretion, composition and functions. Exosomes derived from B16F10 cells exposed to different HS analogues were isolated and characterized by TEM, western blotting and Nanosight analyses. The number, size and protein cargo of exosomes secreted by HS analogues-induced B16F10 cells were detected. The findings indicated the reduced tumor-derived exosome secretion and protein cargo as reflected by lower levels of CD63, TSG101, heparinase and IL-6 in exosomes derived from heparin-induced B16F10 cells as compared with 6-O-desulfated heparin-induced tumor cells. Further functional assays demonstrated that exosomes from tumor cells exposed to heparin weakened tumor proliferation, migration and invasion most significantly among various exosomes derived from B16F10 cells treated with different HS analogues. Moreover, the sulfate group at 6-O position of heparan sulfate has been proved to play an important role in tumor-derived exosome formation and functions. This study suggested a vital view to develop more specific and efficient HS-based strategies in cancer treatment for targeting tumor-derived exosomes.

polymer science,biochemistry & molecular biology,chemistry, applied
λ-Carrageenan Oligosaccharides of Distinct Anti-Heparanase and Anticoagulant Activities Inhibit MDA-MB-231 Breast Cancer Cell Migration

Hugo Groult,Rémi Cousin,Caroline Chot-Plassot,Maheva Maura,Nicolas Bridiau,Jean-Marie Piot,Thierry Maugard,Ingrid Fruitier-Arnaudin

DOI: https://doi.org/10.3390/md17030140

2019-02-27

Marine Drugs

Abstract:In tumor development, the degradation of heparan sulfate (HS) by heparanase (HPSE) is associated with cell-surface and extracellular matrix remodeling as well as the release of HS-bound signaling molecules, allowing cancer cell migration, invasion and angiogenesis. Because of their structural similarity with HS, sulfated polysaccharides are considered a promising source of molecules to control these activities. In this study, we used a depolymerisation method for producing λ-carrageenan oligosaccharides (λ-CO), with progressive desulfation over time. These were then used to investigate the influence of polymeric chain length and degree of sulfation (DS) on their anti-HPSE activity. The effects of these two features on λ-CO anticoagulant properties were also investigated to eliminate a potential limitation on the use of a candidate λ-CO as a chemotherapeutic agent. HPSE inhibition was mainly related to the DS of λ-CO, however this correlation was not complete. On the other hand, both chain length and DS modulated λ-CO activity for factor Xa and thrombin IIa inhibition, two enzymes that are involved in the coagulation cascade, and different mechanisms of inhibition were observed. A λ-carrageenan oligosaccharide of 5.9 KDa was identified as a suitable anticancer candidate because it displayed one of the lowest anticoagulant properties among the λ-CO produced, while showing a remarkable inhibitory effect on MDA-MB-231 breast cancer cell migration.

pharmacology & pharmacy,chemistry, medicinal
In Situ Heparan Sulfate-Induced Peptide Self-Assembly to Overcome the Cell Surface Glycocalyx Barrier for Cancer Treatment

Pengfei Pei,Long Chen,Xinyao Guan,Peng Wei,Xiaoxu Kang,Lili Gong,Lihong Liu,Wenxu Guo,Renji Gu,Lixin Wang,Chuanke Zhao,Jun F Liang,Shi-Zhong Luo

DOI: https://doi.org/10.1021/acsami.4c09243

2024-09-04

Abstract:Heparan sulfate (HS) is a major component of cell surface glycocalyx with extensive negative charges and plays a protective role by preventing toxins, including small molecule drugs and anticancer cationic lytic peptides (ACLPs), from cells. However, this effect may compromise the treatment efficiency of anticancer drugs. To overcome the impedance of cancer cell glycocalyx, an HS-targeting ACLP PTP-7z was designed by fusion of an ACLP and a Zn2+-binding HS-targeting peptide. Upon Zn2+ ion binding, PTP-7z could self-assemble into uniform nanoparticles and show improved serum stability and reduced hemolysis, which enable it to self-deliver to tumor sites. The peptide PTP-7z showed a pH- and Zn2+ ion-dependent HS-binding ability, which triggers the HS-induced in situ self-assembling on the cancer cell surface in the acidic tumor microenvironment (TME). The self-assembled PTP-7z can overcome the impedance of cell glycocalyx by either disrupting cell membranes or translocating into cells through endocytosis and inducing cell apoptosis. Moreover, PTP-7z can also inhibit cancer cell migration. These results proved that HS-responsive in situ self-assembling is a practical strategy to overcome the cancer cell glycocalyx barrier for ACLPs and could be extended to the design of other peptide drugs to promote their in vivo application.
Ince-Gaussian modes of the paraxial wave equation and stable resonators.

M. Bandres,J. Gutiérrez-Vega

DOI: https://doi.org/10.1364/JOSAA.21.000873

2004-05-01

Abstract:We present the Ince-Gaussian modes that constitute the third complete family of exact and orthogonal solutions of the paraxial wave equation in elliptic coordinates and that are transverse eigenmodes of stable resonators. The transverse shape of these modes is described by the Ince polynomials and is structurally stable under propagation. Ince-Gaussian modes constitute the exact and continuous transition modes between Laguerre- and Hermite-Gaussian modes. The expansions between the three families are derived and discussed. As with Laguerre-Gaussian modes, it is possible to construct helical Ince-Gaussian modes that exhibit rotating phase features whose intensity pattern is formed by elliptic rings and whose phase rotates elliptically.
Development of a Novel, Potent, and Selective Sialyltransferase Inhibitor for Suppressing Cancer Metastasis

Han-En Tsai,Chia-Ling Chen,Tzu-Ting Chang,Chih-Wei Fu,Wei-Chia Chen,Ser John Lynon P Perez,Pei-Wen Hsiao,Ming-Hong Tai,Wen-Shan Li

DOI: https://doi.org/10.3390/ijms25084283

2024-04-12

Abstract:Sialyltransferase-catalyzed membrane protein and lipid glycosylation plays a vital role as one of the most abundant post-translational modifications and diversification reactions in eukaryotes. However, aberrant sialylation has been associated with cancer malignancy and metastasis. Sialyltransferases thus represent emerging targets for the development of small molecule cancer drugs. Herein, we report the inhibitory effects of a recently discovered lithocholic acid derivative FCW393 on sialyltransferase catalytic activity, integrin sialyation, cancer-associated signal transduction, MDA-MB-231 and B16F10 cell migration and invasion, and in in vivo studies, on tumor growth, metastasis, and angiogenesis. FCW393 showed effective and selective inhibition of the sialyltransferases ST6GAL1 (IC50 = 7.8 μM) and ST3GAL3 (IC50 = 9.45 μM) relative to ST3GAL1 (IC50 > 400 μM) and ST8SIA4 (IC50 > 100 μM). FCW393 reduced integrin sialylation in breast cancer and melanoma cells dose-dependently and downregulated proteins associated with the integrin-regulated FAK/paxillin and GEF/Rho/ROCK pathways, and with the VEGF-regulated Akt/NFκB/HIF-1α pathway. FCW393 inhibited cell migration (IC50 = 2.6 μM) and invasion in in vitro experiments, and in in vivo studies of tumor-bearing mice, FCW393 reduced tumor size, angiogenesis, and metastatic potential. Based on its demonstrated selectivity, cell permeability, relatively low cytotoxicity (IC50 = 55 μM), and high efficacy, FCW393 shows promising potential as a small molecule experimental tool compound and a lead for further development of a novel cancer therapeutic.
Synthesis of α‐Hydroxy‐1,2,3‐Triazole‐linked Sialyltransferase Inhibitors and Evaluation of Selectivity Towards ST3GAL1, ST6GAL1 and ST8SIA2

Rémi Szabo,Chris Dobie,Andrew Montgomery,Harrison Steele,Haibo Yu,Danielle Skropeta

DOI: https://doi.org/10.1002/cmdc.202400088

IF: 3.54

2024-05-19

ChemMedChem

Abstract:Tumour‐derived sialoglycans, bearing the charged nonulosonic sugar sialic acid at their termini, play a critical role in tumour cell adhesion and invasion, as well as evading cell death and immune surveillance. Sialyltransferases (ST), the enzymes responsible for the biosynthesis of sialylated glycans, are highly upregulated in cancer, with tumour hypersialylation strongly correlated with tumour growth, metastasis and drug resistance. As a result, desialylation of the tumour cell surface using either targeted delivery of a pan‐ST inhibitor (or sialidase) or systemic delivery of a non‐toxic selective ST inhibitors are being pursued as potential new anti‐metastatic strategies against multiple cancers including pancreatic, ovarian, breast, melanoma and lung cancer. Herein, we have employed molecular modelling to give insights into the selectivity observed in a series of selective ST inhibitors that incorporate a uridyl ring in place of the cytidine of the natural donor (CMP‐Neu5Ac) and replace the charged phosphodiester linker of classical ST inhibitors with a neutral a‐hydroxy‐1,2,3‐triazole linker. The inhibitory activities of the nascent compounds were determined against recombinant human ST enzymes (ST3GAL1, ST6GAL1, ST8SIA2) showing promising activity and selectivity towards specific ST sub‐types. Our ST inhibitors are non‐toxic and show improved synthetic accessibility and drug‐likeness compared to earlier nucleoside‐based ST inhibitors.

pharmacology & pharmacy,chemistry, medicinal
Development of Novel Silyl Cyanocinnamic Acid Derivatives as Metabolic Plasticity Inhibitors for Cancer Treatment

Grady L. Nelson,Conor T. Ronayne,Lucas N. Solano,Sravan K. Jonnalagadda,Shirisha Jonnalagadda,Jon Rumbley,Jon Holy,Teresa Rose-Hellekant,Lester R. Drewes,Venkatram R. Mereddy

DOI: https://doi.org/10.1038/s41598-019-54709-7

IF: 4.6

2019-12-01

Scientific Reports

Abstract:Abstract Novel silyl cyanocinnamic acid derivatives have been synthesized and evaluated as potential anticancer agents. In vitro studies reveal that lead derivatives 2a and 2b have enhanced cancer cell proliferation inhibition properties when compared to the parent monocarboxylate transporter (MCT) inhibitor cyano-hydroxycinnamic acid (CHC). Further, candidate compounds exhibit several-fold more potent MCT1 inhibition properties as determined by lactate-uptake studies, and these studies are supported by MCT homology modeling and computational inhibitor-docking studies. In vitro effects on glycolysis and mitochondrial metabolism also illustrate that the lead derivatives 2a and 2b lead to significant effects on both metabolic pathways. In vivo systemic toxicity and efficacy studies in colorectal cancer cell WiDr tumor xenograft demonstrate that candidate compounds are well tolerated and exhibit good single agent anticancer efficacy properties.

multidisciplinary sciences
Antitumor activities of novel glycyrrhetinic acid-modified lipogel hybrid system in vitro

Hu, Yan

DOI: https://doi.org/10.1007/s10853-023-08394-7

IF: 4.5

2023-03-28

Journal of Materials Science

Abstract:Currently, conventional chemotherapy for hepatocellular carcinoma is limited and has serious side effects due to premature release and limited lesion targeting recognition. In this study, to further address the challenges of drug delivery for liver cancer, a novel hybrid lipid–polymer nanocomposite, glycyrrhetinic acid-modified lipogel (GA-SS-LG), was designed to merge the beneficial features of both polymer-based and lipid-based delivery systems in a single nanocarrier, which was proposed as a liposome with a bifunctional ligand as well as a polymer gel core inside in the liposome. The inhibitory effect of the GA-SS-LG on HepG2 cells was studied in vitro by using curcumin (Cur) as a model drug. The experimental results show that the incorporation of the polymer gel core improved the stability of the liposomes and had the ability to enhance drug encapsulation and delay drug release. At the same time, the liposome outer membrane could be modified with functional ligands to deliver drugs accurately. Our system accurately delivers drugs to tumor cells and responds quickly to release the loaded drugs in large quantities. This study improves the antitumor activity of Cur by preparing a lipogel composite system and provides a new formulation that combines both the polymer-based and lipid-based delivery systems in a single nanocarrier for the clinical application of antitumor drugs.

materials science, multidisciplinary
A novel PEGylated liposome-encapsulated SANT75 suppresses tumor growth through inhibiting hedgehog signaling pathway.

Yike Yuan,Yuwei Zhao,Shengchang Xin,Ni Wu,Jiaolin Wen,Song Li,Lijuan Chen,Yuquan Wei,Hanshuo Yang,Shuo Lin

DOI: https://doi.org/10.1371/journal.pone.0060266

IF: 3.7

2013-01-01

PLoS ONE

Abstract:The Hedgehog (Hh) pathway inhibitors have shown great promise in cancer therapeutics. SANT75, a novel compound we previously designed to specially inhibit the Smoothened (SMO) protein in the Hh pathway, has greater inhibitory potency than many of commonly used Hh inhibitors. However, preclinical studies of SANT75 revealed water insolubility and acute toxicity. To overcome these limitations, we developed a liposomal formulation of SANT75 and investigated its antitumor efficacy in vitro and in vivo. We encapsulated SANT75 into PEGylated liposome and the mean particle size distribution and zeta-potential (ZP) of liposomes were optimized. Using the Shh-light2 cell and Gli-GFP or Flk-GFP transgenic reporter zebrafish, we confirmed that liposome-encapsulated SANT75 inhibited Hh activity with similar potency as the original SANT75. SANT75 encapsulated into liposome exerted strong tumor growth-inhibiting effects in vitro and in vivo. In addition, the liposomal SANT75 therapy efficiently improved the survival time of tumor-bearing mice without obvious systemic toxicity. The pathological morphology and immunohistochemistry staining revealed that liposomal SANT75 induced tumor cell apoptosis, inhibited tumor angiogenesis as assessed by CD31 and down-regulated the expression of Hh target protein Gli-1 in tumor tissues. Our findings suggest that liposomal formulated SANT75 has improved solubility and bioavailability and should be further developed as a drug candidate for treating tumors with abnormally high Hh activity.
Suppress Orthotopic Colon Cancer and Its Metastasis Through Exact Targeting and Highly Selective Drug Release by a Smart Nanomicelle.

Chunqi Zhu,Hanbo Zhang,Wei Li,Lihua Luo,Xiaomeng Guo,Zuhua Wang,Fenfen Kong,Qingpo Li,Jie Yang,Yongzhong Du,Jian You

DOI: https://doi.org/10.1016/j.biomaterials.2018.01.043

IF: 14

2018-01-01

Biomaterials

Abstract:The treatment of metastatic cancer is a huge challenge at the moment. Highly precise targeting delivery and drug release in tumor have always been our pursuit in cancer therapy, especially to advance cancer with metastasis, for increasing the efficacy and biosafety. We established a smart nanosized micelle, formed by tocopherol succinate (TOS) conjugated hyaluronic acid (HA) using a disulfide bond linker. The micelle (HA-SS-TOS, HSST) can highly specifically bind with CD44 receptor over-expressed tumor, and response selectively to high GSH level in the cells, inducing disulfide bond breakage and the release of the payload (paclitaxel, PTX). To predict the antitumor efficacy of the micelles more clinically, we established an orthotopic colon cancer model with high metastasis rate, which could be visualized by the luciferase bioluminescence. Our data confirmed CD44 high expression in the colon cancer cells. Highly matching between the micellar fluorescence and bioluminescence of cancer cells in intestines demonstrated an exact recognition of our micelles to orthotopic colon tumor and its metastatic cells, attributing to the mediation of CD44 receptors. Furthermore, the fluorescence of the released Nile Red from the micelles was found only in the tumor and its metastatic cells, and almost completely overlapped with the bioluminescence of the cancer cells, indicating a highly selective drug release. Our micelles presented an excellent therapeutic effect against metastatic colon cancer, and induced significantly prolonged survival time for the mice, which might become a promising nanomedicine platform for the future clinical application against advanced cancers with high CD44 receptor expression.

[Proceedings: Evaluation of serum dopamine-beta-hydroxylase determination].

Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo

A New Synthesized Dicarboxylated Oxy-Heparin Efficiently Attenuates Tumor Growth and Metastasis

Targeted glycan degradation potentiates the anticancer immune response in vivo

Design Principle of Heparanase Inhibitors: A Combined In Vitro and In Silico Study

Chemoenzymatic synthesis of sulfur-linked sugar polymers as heparanase inhibitors

Non-Anticoagulant Heparan Sulfate from the Ascidian Phallusia nigra Prevents Colon Carcinoma Metastasis in Mice by Disrupting Platelet-Tumor Cell Interaction

Epigenetic Targeting of Heparan Sulfate 3- O- and 6- O-Sulfation in Breast Cancer Cells: Prospects for Attenuating Prothrombotic Tumor Cell Activities

Abstract 3105: Design principle of heparanase inhibitors: A combined in vitro and in silico study

Synthesis and Detection of BODIPY‐, Biotin‐, and 19F‐ Labeled Single‐Entity Dendritic Heparan Sulfate Mimetics

Non-anticoagulant heparins and inhibition of cancer

Heparan sulfate analogues regulate tumor-derived exosome formation that attenuates exosome functions in tumor processes

λ-Carrageenan Oligosaccharides of Distinct Anti-Heparanase and Anticoagulant Activities Inhibit MDA-MB-231 Breast Cancer Cell Migration

In Situ Heparan Sulfate-Induced Peptide Self-Assembly to Overcome the Cell Surface Glycocalyx Barrier for Cancer Treatment

Ince-Gaussian modes of the paraxial wave equation and stable resonators.

Development of a Novel, Potent, and Selective Sialyltransferase Inhibitor for Suppressing Cancer Metastasis

Synthesis of α‐Hydroxy‐1,2,3‐Triazole‐linked Sialyltransferase Inhibitors and Evaluation of Selectivity Towards ST3GAL1, ST6GAL1 and ST8SIA2

Development of Novel Silyl Cyanocinnamic Acid Derivatives as Metabolic Plasticity Inhibitors for Cancer Treatment

Antitumor activities of novel glycyrrhetinic acid-modified lipogel hybrid system in vitro

A novel PEGylated liposome-encapsulated SANT75 suppresses tumor growth through inhibiting hedgehog signaling pathway.

Suppress Orthotopic Colon Cancer and Its Metastasis Through Exact Targeting and Highly Selective Drug Release by a Smart Nanomicelle.